Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Summary of 2025 Society of Toxicology Workshop “Vaccine Toxicology in the Post-COVID Era”. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
2014 · External reference
Unresolved reference
2005 · External reference
Dose site reactions and related findings after vaccine administration in safety studies
10.1002/jat.3314 · 2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Evaluation of non-clinical toxicity studies of COVID-19 vaccines
10.1016/j.yrtph.2023.105438 · 2023 · External reference
Unresolved reference
External reference
Are repeat-dose toxicity studies informative for safety assessment of vaccine candidates? A survey of vaccine developers
10.1177/10915818241293371 · 2024 · External reference
The 60-year evolution of lipid nanoparticles for nucleic acid delivery
10.1038/s41573-024-00977-6 · 2024 · External reference
Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach
10.1186/s12951-024-02972-w · 2024 · External reference
Solid lipid nanoparticles production, characterization and applications
10.1016/s0169-409x(01)00105-3 · 2001 · External reference
Lipid nanoparticles: production, characterization and stability
2014 · External reference
Delivering the messenger: advances in technologies for therapeutic mRNA delivery
10.1016/j.ymthe.2019.02.012 · 2019 · External reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · 2022 · External reference
Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application
10.15171/apb.2015.043 · 2015 · External reference
An ionizable lipid toolbox for RNA delivery
10.1038/s41467-021-27493-0 · 2021 · External reference
Lipid nanoparticles for mRNA delivery
10.1038/s41578-021-00358-0 · 2021 · External reference
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
10.1038/s41467-019-12275-6 · 2019 · External reference
Structure and function of cationic and ionizable lipids for nucleic acid delivery
10.1007/s11095-022-03460-2 · 2023 · External reference
Self-assembled mRNA vaccines
10.1016/j.addr.2020.12.014 · 2021 · External reference
Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses
10.1016/j.ymthe.2017.03.035 · 2017 · External reference
mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials
10.1016/j.vaccine.2019.04.074 · 2019 · External reference
Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape
10.1038/nbt.2612 · 2013 · External reference
Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale
10.1083/jcb.202110137 · 2021 · External reference
A systematic study of unsaturation in lipid nanoparticles leads to improved mRNA transfection in vivo
10.1002/anie.202013927 · 2021 · External reference
Rational design of cationic lipids for siRNA delivery
10.1038/nbt.1602 · 2010 · External reference
Vaccine manufacturing
2013 · External reference
Unresolved reference
External reference
MRNA vaccine era—mechanisms, drug platform and clinical prospection
10.3390/ijms21186582 · 2020 · External reference
mRNA vaccines manufacturing: challenges and bottlenecks
10.1016/j.vaccine.2021.03.038 · 2021 · External reference
Liposome: composition, characterisation, preparation, and recent innovation in clinical applications
10.1080/1061186x.2018.1527337 · 2019 · External reference
Exploring the landscape of lipid nanoparticles (LNPs): a comprehensive review of LNPs types and biological sources of lipids
2024 · External reference
mRNA vaccines — a new era in vaccinology
10.1038/nrd.2017.243 · 2018 · External reference
How manufacturing won or lost the COVID-19 vaccine race
10.1016/j.vaccine.2023.12.031 · 2024 · External reference
Resources, production scales and time required for producing RNA vaccines for the global pandemic demand
10.3390/vaccines9010003 · 2020 · External reference
Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and/or anionic charges). Data review suggests an emerging pattern
10.1016/j.toxlet.2023.07.011 · 2023 · External reference
Liposome and immune system interplay: challenges and potentials
10.1016/j.jconrel.2019.05.030 · 2019 · External reference
Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery
10.3390/vaccines12101148 · 2024 · External reference
The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
10.1016/j.isci.2021.103479 · 2021 · External reference
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
10.1016/j.immuni.2021.11.001 · 2021 · External reference
Committee IHV and ASP Safety of vaccine adjuvants: focus on autoimmunity
10.1016/j.vaccine.2015.01.073 · 2015 · External reference
Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach
10.1016/j.cmi.2023.12.010 · 2024 · External reference
Vaccine safety issues at the turn of the 21st century
2021 · External reference
Myocarditis associated with COVID-19 vaccination
10.1038/s41541-024-00893-1 · 2024 · External reference
Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory Committee on immunization practices — United States, June 2021
10.15585/mmwr.mm7027e2 · 2021 · External reference
Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination ☆
10.1016/j.hlc.2021.07.011 · 2021 · External reference
Incidence, risk factors, natural history, and hypothesized mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review
10.1136/bmj-2021-069445 · 2022 · External reference
Toxicological assessments of a pandemic COVID-19 vaccine—demonstrating the suitability of a platform approach for mRNA vaccines
10.3390/vaccines11020417 · 2023 · External reference
Nonclinical safety assessment of lipid nanoparticle-and emulsion-based self-amplifying mRNA vaccines in rats
10.1177/10915818221138781 · 2023 · External reference
Development of COVID-19 therapies: nonclinical testing considerations
10.1016/j.yrtph.2022.105189 · 2022 · External reference
Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
10.1038/s41541-024-00980-3 · 2024 · External reference
Unresolved reference
2022 · External reference
Future use of rabbits in safety assessment regulatory studies
2026 · External reference
Rational design of lipid nanoparticles for enabling gene therapies
10.1016/j.omtm.2025.101518 · 2025 · External reference
On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA
10.1021/acsnano.8b01516 · 2018 · External reference
Unresolved reference
External reference
mRNA vaccines for infectious diseases — advances, challenges and opportunities
10.1038/s41573-024-01042-y · 2024 · External reference
N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting
10.1038/s41586-023-06800-3 · 2024 · External reference
Nonclinical safety assessment of an mRNA Covid-19 vaccine candidate following repeated administrations and biodistribution
10.1002/jat.4548 · 2024 · External reference
Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals
10.1038/s41598-025-07661-8 · 2025 · External reference
Vaccine-associated enhanced disease and pathogenic human coronaviruses
10.3389/fimmu.2022.882972 · 2022 · External reference
Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data
10.1016/j.vaccine.2021.01.055 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Evidence-based assessment of safety and mechanistic questions related to mRNA COVID-19 vaccines
10.1016/j.vaccine.2026.128394 · 2026 · External reference
Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization
10.1016/s0140-6736(24)00850-x · 2024 · External reference
The safety evaluation of adjuvants during vaccine development: the AS04 experience
10.1016/j.vaccine.2011.04.046 · 2011 · External reference
Non-clinical safety assessment of single and repeated administration of gE/AS01 zoster vaccine in rabbits
10.1002/jat.3329 · 2017 · External reference
Effects of adjuvant systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats
10.1016/j.yrtph.2015.06.003 · 2015 · External reference
Intramuscularly administered herpes zoster subunit vaccine has no effects on fertility, pre- and post-natal development in sprague-dawley rats
10.1016/j.reprotox.2017.03.015 · 2017 · External reference
